PETALING JAYA: The government has accepted the tender offer from Duopharma Biotech Bhd
’s wholly-owned subsidiary, Duopharma Marketing Sdn Bhd and Biocon Sdn Bhd to supply products under the Health Ministry’s procurement, worth RM65.08mil.
In a filing with Bursa Malaysia, Duopharma said the duration of the contract shall be until May 15, 2026.
“With an estimated 4.75 million diabetics in Malaysia, of which about 450,000 patients are treated with human insulin in government hospitals and clinics, DMktg and Biocon hope to improve diabetes management in the country by providing high quality and cost-effective biosimilar insulins.”
Separately, Duopharma said its wholly-owned subsidiary, Duopharma (M) Sendirian Bhd, has secured a contract from the government worth RM52.54mil for the supply of insulin injection.
It said the duration of this contract shall be until Feb 5, 2028.
